Resveratrol ameliorates nutritional steatohepatitis through the mmumiR599/PXR pathway

Lingbo Kong1, Xinyu An1, Lingxi Hu1

  • 1Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China.

Insights

Resveratrol effectively treats non-alcoholic steatohepatitis (NASH) by regulating the mmu-miR-599/PXR pathway, reducing liver inflammation and injury. This study highlights resveratrol

Area of Science:

  • Hepatology and Gastroenterology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-alcoholic steatohepatitis (NASH) is a progressive liver disease characterized by fat accumulation, inflammation, and hepatocellular injury.
  • Current therapeutic options for NASH are limited, necessitating the exploration of novel treatment strategies.

Purpose of the Study:

  • To investigate the therapeutic effects of resveratrol on non-alcoholic steatohepatitis (NASH) in a mouse model and Hepa1-6 cells.
  • To elucidate the molecular mechanisms underlying resveratrol's action, focusing on the mmu-miR-599/PXR pathway and inflammatory responses.

Main Methods:

  • Induction of steatohepatitis in C57BL/6J mice using a methionine-choline-deficient (MCD) diet, followed by resveratrol treatment.
  • Establishment of a NASH cell model in Hepa1-6 cells using palmitic acid, with subsequent treatment with resveratrol, mmu-miR-599 mimic/inhibitor, or PXR plasmid.
  • Analysis of liver histology, serum biochemistry, and gene/protein expression of mmu-miR-599, PXR, and inflammatory markers using RT-qPCR and western blotting.
  • Luciferase activity assay to confirm the binding site of mmu-miR-599 in PXR mRNA.

Main Results:

  • MCD diet-induced NASH in mice led to steatosis, necrosis, and inflammation, which were ameliorated by resveratrol treatment.
  • Resveratrol significantly reduced liver injury markers and inflammatory gene expression (NF-κB, TNF-α, IL-1β, IL-6, NLRP3, STAT3).
  • In Hepa1-6 cells, resveratrol decreased mmu-miR-599 expression and increased PXR expression, while mmu-miR-599 mimic inhibited PXR and its overexpression suppressed inflammatory factors. A direct interaction between mmu-miR-599 and PXR mRNA was confirmed.

Conclusions:

  • Resveratrol demonstrates a protective role in ameliorating NASH by modulating the mmu-miR-599/PXR pathway.
  • The mechanism involves the downregulation of mmu-miR-599, leading to increased PXR expression and subsequent suppression of inflammatory pathways.
  • Resveratrol holds potential as a therapeutic candidate for managing NASH.